Brian Zasitko - Lobe Sciences Chief Officer
| LOBEF Stock | USD 0.02 0.02 844.44% |
Insider
Brian Zasitko is Chief Officer of Lobe Sciences
| Web | https://www.lobesciences.com |
Lobe Sciences Management Efficiency
The company has return on total asset (ROA) of (0.6505) % which means that it has lost $0.6505 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (2.7981) %, meaning that it generated substantial loss on money invested by shareholders. Lobe Sciences' management efficiency ratios could be used to measure how well Lobe Sciences manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Robert Madden | Grey Cloak Tech | 51 | |
| Greg Gould | Charlottes Web Holdings | N/A | |
| Tim Orr | Charlottes Web Holdings | N/A | |
| Perry Antelman | Charlottes Web Holdings | 59 | |
| Andres Gortari | Charlottes Web Holdings | 47 | |
| Jared Stanley | Charlottes Web Holdings | 35 | |
| Roman Nemchenko | Ascend Wellness Holdings | N/A | |
| Christopher Melillo | Ascend Wellness Holdings | 49 | |
| Abner Kurtin | Ascend Wellness Holdings | 56 | |
| Jacques Tortoroli | Charlottes Web Holdings | 64 | |
| Cory Pala | Charlottes Web Holdings | N/A | |
| Brian Miesieski | Ascend Wellness Holdings | N/A | |
| Jason Liotta | Ascend Wellness Holdings | N/A | |
| David Gacom | Ascend Wellness Holdings | N/A | |
| Rebecca BSc | Ascend Wellness Holdings | N/A | |
| Stephen Rogers | Charlottes Web Holdings | 57 | |
| Robin Debiase | Ascend Wellness Holdings | 52 | |
| Eric Shoemaker | C21 Investments | N/A | |
| Sonny Newman | C21 Investments | N/A | |
| Scott Landers | Grey Cloak Tech | N/A | |
| Kevin Pitts | Grey Cloak Tech | 63 | |
Management Performance
| Return On Equity | -2.8 | |||
| Return On Asset | -0.65 |
Lobe Sciences Management Team
Elected by the shareholders, the Lobe Sciences' board of directors comprises two types of representatives: Lobe Sciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lobe. The board's role is to monitor Lobe Sciences' management team and ensure that shareholders' interests are well served. Lobe Sciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lobe Sciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Philip Young, Corp CEO | ||
| Brian Zasitko, Chief Officer | ||
| Maghsoud Dariani, Chief Officer |
Lobe Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Lobe Sciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.8 | |||
| Return On Asset | -0.65 | |||
| Current Valuation | (6.77 M) | |||
| Shares Outstanding | 76.97 M | |||
| Shares Owned By Insiders | 2.85 % | |||
| Price To Earning | 1.34 X | |||
| Price To Book | 0.76 X | |||
| Price To Sales | 7.72 X | |||
| Gross Profit | 841.56 K | |||
| EBITDA | (4.11 M) |
Currently Active Assets on Macroaxis
Other Information on Investing in Lobe OTC Stock
Lobe Sciences financial ratios help investors to determine whether Lobe OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Lobe with respect to the benefits of owning Lobe Sciences security.